
        <!DOCTYPE html>
        <html>
        <head>
            <title>Celldex Therapeutics Inc. (CLDX) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Celldex Therapeutics Inc. (CLDX)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">11</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">5</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">4</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">-0.04</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e86c63704e4d2849e443c0e11548ebbf5ae9fe0b82a96a7e8060735e27cad366" target="_blank" rel="noopener noreferrer">Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4f2f9d09b65abb249707de6c5eafa302611828d2c9bbacc5e00e0c23aa24a16c" target="_blank" rel="noopener noreferrer">Celldex Therapeutics, Inc.(NasdaqCM: CLDX) dropped from Russell Small Cap Comp Growth Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.97
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc. dropped from Russell Small Cap Comp Growth Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7c7bca40bf43ab1ecf99f04eb3c65363627c0cf2273a535e29fa6826443d40e2" target="_blank" rel="noopener noreferrer">Celldex Therapeutics, Inc.(NasdaqCM: CLDX) dropped from Russell 3000 Growth Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.97
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc. dropped from Russell 3000 Growth Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fb80907643579cac3542e9a16501989b9d02322131d1f623046b3651ad7dc4cc" target="_blank" rel="noopener noreferrer">Celldex Therapeutics, Inc.(NasdaqCM: CLDX) dropped from Russell 2500 Growth Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.96
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc. dropped from Russell 2500 Growth Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d7db678a5f3d398e9555a59c3d268611c286e03caeecf999b5ffc468f05ba61b" target="_blank" rel="noopener noreferrer">Celldex Therapeutics, Inc.(NasdaqCM: CLDX) dropped from Russell 2000 Growth Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-29</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.97
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc. dropped from Russell 2000 Growth Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8c660616874e8ba304ad93c79f1854e59b06f8b727edfc1f95e407180a5a0d5d" target="_blank" rel="noopener noreferrer">Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-16</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">HAMPTON - Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=603299c54d71760971350adbc51d5ae4dd8e9b63cca89a58cfaf306ca882cbeb" target="_blank" rel="noopener noreferrer">Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema¬†in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-14</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9add0f977e8704ef16aa19482859a8fb985d2575c8791f24a8ee403f6e310db2" target="_blank" rel="noopener noreferrer">Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-13</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.83
                                </span>
                            </div>
                            <div class="article-summary">Celldex announced new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aa41d3f5fc5dd04aa21a81a9a530352e67d354c0bc0e8425758f6b42aa9e8748" target="_blank" rel="noopener noreferrer">Transcript : Celldex Therapeutics, Inc. - Special Call</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-12</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Presentation Operator MessageOperator Hello. Welcome to Celldex's conference call and webcast. [Operator Instructions] I would now like to turn the conference over to Sarah Cavanaugh. You may......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=11465b656726074a769064172d5d9289181b0054f0b3aa305697b6a101b75fe1" target="_blank" rel="noopener noreferrer">Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=88c1eb41f7d5547914e048804204e1767141ddcc7237b85640b346c3bb5b9b02" target="_blank" rel="noopener noreferrer">Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Company to host webcast on Thursday, June 12 at 6:00 pm ETHAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company‚Äôs Phase 2 study of barzolvol...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        